EGFR and lung adenocarcinoma: Adenocarcinomas with psammoma bodies are often associated with tyrosine kinase inhibitor-targetable driver mutations in EGFR (69.8%), ALK (13.2%), and ROS1 (1.9%) [6], although the presence of psammoma bodies in ROS1-fused lung adenocarcinomas remains debated.